the purpose of this paper is to make explicit how companies in pharmaceutical sector can ensure their position in different markets by relying on a sustainable competitive advantages resulted from using a good defined marketing model. various factors are highlighted including high research and development roles and costs, hard government regulation in frame of gmp standard, market analysis tool...

Industrial renewal in the bio/nanopharma sector is important for the long term strength of the Australian economy and for the health of its citizens. A variety of factors, however, may have caused inadequate attention to focus on systematically promoting domestic generic and small biotechnology manufacturers in Australian health policy. Despite recent clarifications of 'springboarding' capacity...

BACKGROUND Pharmaceutical industry involvement in biomedicine has produced major benefits but has also caused concern. At present, there is no consensus as to how medical and government organizations should relate to the pharmaceutical industry and this is partly due to the absence of systematic study of the various alternatives. In Australia industry cooperation has been elicited through the '...

This paper is an in depth analysis of the influence that investment into research and development has on a firm’s profitability in the pharmaceutical industry in the United States. The pharmaceutical industry is chosen due to its high intensity of research and development expenditures. The top 16 companies in the pharmaceutical industry are analyzed through regression analysis. The argument mad...

BACKGROUND Interactions with the pharmaceutical industry are known to affect the attitudes and behaviors of medical residents; however, to our knowledge, a nationally representative description of current practices has not been reported. METHODS The Association of Program Directors in Internal Medicine surveyed 381 US internal medicine residency program directors in 2006-2007 regarding pharma...

Although biomarkers have been the essence of laboratory medicine since its inception, they are relatively new tools in the development of pharmaceutical compounds. The main utility of biomarkers for pharmaceutical companies has been in making drug development a more efficient and a cost-effective process. This is primarily the case because of the drastic and perhaps alarming increase seen in th...

The pharmaceutical industry is one of the world’s most important production sectors. However, over the last decades, pharmaceutical companies have been facing the urgent need to improve and keep their performances under tight control, an activity they are historically behindhand with, compared to other sectors, such as food or electro-mechanical industries. The increasing speed of new product d...

It is time to stop hiding our heads in the sand when it comes to interactions with the pharmaceutical industry! This is an issue of reality, not ideology. In an ideal world there would be no industry sponsored research and no potential for tainted research. In an ideal world there would be no need for marketing of new drugs to physicians or to the public and all the savings would be passed on t...

The total global pharmaceutical market was estimated at around US $343 billion (bn) in 1999 and registered a 10% growth in 1999 compared to 6-7% p.a. in the past three years. The industry is characterised by high fragmentation with the top ten companies accounting for only around 36% of the prescription pharmaceutical market in 1998. However, consolidation in the industry has resulted in an inc...

The pharmaceutical industry is accountable on the one hand to its shareholders and on the other to the community at large. These two obligations can, in principle, be met. However, the industry has developed practices that do not consider society, including excessive or inappropriate pricing of drugs, an indifference to the needs and limitations of the developing world, an imbalance between tru...